The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib
Open accessAbstract
Key Points: In patients treated with ruxolitinib, harboring ≥3 mutations was inversely correlated with spleen response and time to treatment discontinuation. Multigene profiling may be useful for therapeutic planning.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 6×
“Overall survival, mean (weeks) 207 (7-387) 194 (43-372) 243 (7-387) 246 (60-336) .”
InfluentialJAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms
Rampal, R., Ahn, J., Abdel-Wahab, O., Nahas, M., Wang, K., Lipson, D., Otto, G. A., Yelensky, R., Hricik, T., McKenney, A. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407792111 · Cited by 301
Self-citation
Cited by
Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification
Kamps, R., Brandão, R., Bosch, B., Paulussen, A., Xanthoulea, S., Blok, M., & Romano, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020308 · Cited by 453
Spivak, J. L. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1406186 · Cited by 404
Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants
Chachoua, I., Pecquet, C., El-Khoury, M., Nivarthi, H., Albu, R.-I., Marty, C., Gryshkova, V., Defour, J.-P., Vertenoeil, G., Ngo, A., et al. (2016) · Blood · doi:10.1182/blood-2015-11-681932 · Cited by 349
Araki, M., Yang, Y., Masubuchi, N., Hironaka, Y., Takei, H., Morishita, S., Mizukami, Y., Kan, S., Shirane, S., Edahiro, Y., et al. (2016) · Blood · doi:10.1182/blood-2015-09-671172 · Cited by 299
Investigational Janus kinase inhibitors in development for myelofibrosis
Bose, P., Abou Zahr, A., & Verstovsek, S. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1323871 · Cited by 12
Metadata
- Authors
- Patel, K. P., Newberry, K. J., Luthra, R., Jabbour, E., Pierce, S., Cortes, J., Singh, R., Mehrotra, M., Routbort, M. J., Luthra, M., Manshouri, T., Santos, F. P., Kantarjian, H., & Verstovsek, S.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2015-08-06
- Volume
- 126
- Issue
- 6
- Pages
- 790-797
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1503482160
- Cited by
- 194
- References
- 3
- FWCI
- 11.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. https://app.cochat.ai/papers/10.1182/blood-2015-03-633404
- The paper
- Patel, K. P., Newberry, K. J., Luthra, R., Jabbour, E., Pierce, S., Cortes, J., Singh, R., Mehrotra, M., Routbort, M. J., Luthra, M., Manshouri, T., Santos, F. P., Kantarjian, H., & Verstovsek, S. (2015). Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. https://doi.org/10.1182/blood-2015-03-633404
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.